SLC34A1 Genotype

If kidney stones run in your family, your child had unexplained hypercalcemia, or you developed osteopenia in your thirties or forties without a clear reason, the answer may be written into a single gene you inherited. SLC34A1 (solute carrier family 34 member 1) carries the instructions for one of the principal phosphate-recycling transporters in your kidneys, and inherited variants can quietly tilt your phosphate balance for life.

This test tells you whether you carry one of the variants known to disrupt that transporter. The result does not change. What changes is what you do with it: how aggressively you screen for stones, how carefully you watch your bones, and what conversations you have with your children, siblings, and parents.

What This Gene Actually Does

SLC34A1 codes for a protein called NaPi-IIa (sodium-phosphate cotransporter 2a), which sits on the surface of cells lining the kidney's filtering tubes. Every day your kidneys filter phosphate out of the blood, and NaPi-IIa, together with a related transporter called NaPi-IIc, pulls it back in before urine leaves the body. When the gene works normally, phosphate stays balanced. When variants impair the transporter, phosphate leaks out in the urine.

That phosphate leak sets off a chain reaction. Low blood phosphate suppresses a hormone called FGF-23, which in turn signals the body to make more active vitamin D. The active vitamin D then pulls more calcium out of food and bone. The calcium ends up in the urine, where it can crystallize into stones or chalky deposits in the kidney tissue itself. Bones can lose mineral over time. In infants, the combination can cause hypercalcemia (high blood calcium) severe enough to threaten growth and feeding.

Infantile Hypercalcemia

When a child inherits two faulty copies of SLC34A1 (one from each parent), the result can be a condition called idiopathic infantile hypercalcemia type 2. Babies present with high blood calcium, high calcium in the urine, calcium deposits in the kidneys (nephrocalcinosis), suppressed parathyroid hormone, and elevated active vitamin D. Many fail to thrive.

The phenotype is often dramatic in infancy but tends to improve with age and supportive care, which may include hydration, dietary adjustments, and sometimes phosphate supplementation. Some children, however, progress to chronic kidney disease in adulthood, which is why long-term monitoring matters even after symptoms settle.

Kidney Stones and Bone Loss in Adults

You do not necessarily need two faulty copies to feel the effects. People with a single SLC34A1 variant have been described with recurrent kidney stones, phosphate wasting in urine, low blood phosphate, and unusually early osteopenia or osteoporosis. This pattern has its own name in the medical literature: hypophosphatemic nephrolithiasis and osteoporosis type 1, or NPHLOP1. The pathogenicity of single-copy SLC34A1 variants has been debated, with earlier reports questioned and more recent functional studies providing stronger support for some variants causing disease.

In a study of 235 Pakistani families with kidney stone disease, a likely monogenic cause was identified in about 7 percent of families, and dominant SLC34A1 mutations were the most frequent monogenic cause among that solved subset. Five missense variants impaired phosphate transport when tested in the laboratory. In a separate analysis of adult stone formers, carrying a rare variant in a stone-disease gene was linked to higher stone recurrence over several years of follow-up.

Common Variants and General Stone Risk

Beyond the rare, high-impact mutations, common variation in SLC34A1 has been linked to kidney stone risk in the general population. Genetic analyses suggest that interventions or genetic backgrounds that raise serum phosphate via SLC34A1 would reduce kidney stone risk, implying that relatively lower transporter activity nudges people toward stone formation. Common SLC34A1 variants have also been associated with kidney function and chronic kidney disease susceptibility in large genome-wide studies.

Reconciling Why Both Too Little and Too Much Can Hurt

It can look paradoxical that low transporter activity causes phosphate to leave the body too easily, yet that loss is also what triggers high calcium, stones, and bone problems. The framework that resolves this: SLC34A1 is not a simple good-number or bad-number marker. It sets the position of a balance point between phosphate, calcium, and vitamin D. When that balance is pushed, the body compensates, and the compensations themselves drive disease. The same variant can express as infant hypercalcemia in one person and adult stones with bone thinning in another, depending on dose (one copy or two), other genes, and life stage.

Fanconi Syndrome and Kidney Function

In rarer cases, certain SLC34A1 mutations cause renal Fanconi syndrome, a generalized failure of the kidney's proximal tube to reabsorb not just phosphate but a range of small molecules. This presentation includes hypophosphatemic rickets and progressive kidney dysfunction. Cohort studies of carriers show that biallelic SLC34A1 and SLC34A3 variants produce distinct but overlapping phenotypes. In several published case series, oral phosphate supplementation has helped normalize urinary calcium excretion and improve growth, though management can be complex and benefits from specialist input.

A One-Time Test, Acted On for Life

Your SLC34A1 genotype does not change. You inherit it at conception and carry the same sequence at age 5, 35, and 75. There is no value in retesting the gene itself. The value comes from integrating the result into decisions you make over decades.

If you carry a pathogenic variant, the recommended cadence shifts to ongoing monitoring of the downstream measurements that do change: serum phosphate and calcium, urinary calcium and phosphate, 24-hour urine stone risk panels, active and storage forms of vitamin D, parathyroid hormone, and bone density. Get a baseline of these companion tests when you receive your genetic result, and revisit them at least annually, or more often if you are starting an intervention. Renal ultrasound is also commonly used to look for nephrocalcinosis or stones.

What to Do With an Unexpected Result

A positive SLC34A1 finding is not a diagnosis on its own. It is a signal to investigate further and to plan. The decision pathway usually involves:

• Confirmatory workup: order a full mineral panel (serum phosphate, calcium, ionized calcium, parathyroid hormone, 25-hydroxy and 1,25-dihydroxy vitamin D) and a 24-hour urine for calcium, phosphate, and stone risk factors.
• Imaging: a kidney ultrasound to check for nephrocalcinosis or existing stones, even if you have never had symptoms.
• Bone assessment: a DEXA scan if you are an adult, especially if you are under 50 or have any history of low-impact fractures.
• Specialist referral: a nephrologist for kidney and stone management, an endocrinologist for the bone-mineral side, and a genetic counselor to interpret the variant and discuss family implications.
• Family conversations: biological children, siblings, and parents share your DNA. Cascade testing is the standard approach when a pathogenic variant is found in one family member.

Penetrance and What Carrying a Variant Really Means

Carrying a risk variant does not guarantee you will develop the associated disease. Geneticists call this concept penetrance: the fraction of people with a given variant who actually go on to show the condition. SLC34A1 has variable penetrance, especially for single-copy variants. Some carriers have lifelong recurrent stones and early bone loss. Others have only subtle biochemical signs. A few never develop noticeable disease at all. The result tells you about elevated baseline risk, not destiny.

When Results Can Be Misleading

Genetic test interpretation has its own set of confounders that are different from those that affect ordinary blood tests.

• Variant panel coverage: the test only detects the specific variants it is designed to read. A negative result does not rule out other rare or novel variants in SLC34A1 that the panel does not include.
• Ancestry-specific frequencies: some SLC34A1 variants are common in one population and rare in another. The risk profile interpreted from a result depends partly on ancestral background. A large analysis of more than 141,000 individuals showed substantial inter-ethnic differences in solute carrier variant frequencies, including SLC34A1.
• Variants of uncertain significance: sequencing can return changes whose clinical meaning is not yet established. A VUS (variant of uncertain significance) result is not the same as a known pathogenic variant and should not drive aggressive action without further evaluation.
• Uncertain functional impact of some variants: not every variant labeled pathogenic produces disease in every person or model. For example, a SLC34A1 variant common in some populations did not produce a phenotype in mice even when both copies were affected, which is one reason interpretation should be done with a clinician.
• Direct-to-consumer reports: a result from a recreational genetic test is not equivalent to a clinical-grade SLC34A1 panel, which uses more accurate methods and analyzes a broader set of variants. If your only prior data is from a consumer test, a clinical retest by a different method may be warranted.